A Study of the Safety and Pharmacokinetics of an Anti-Inflammatory Therapeutic Antibody (MABp1) in Patients With Type 2 Diabetes

Type 2 Diabetes Clinical Trial

Official title:

A Phase II Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of an Anti-Inflammatory Therapeutic Antibody (MABp1) in Patients With Type 2 Diabetes

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01427699
• Other study ID #: 2010-PT011
• Status: Completed
• Phase: Phase 2
• Start date: June 30, 2011

Study information

• Verified date: February 2021
• Source: Janssen Research & Development, LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine if T2-18C3, a true human monoclonal antibody that blocks inflammation, is safe to use in patients with type 2 diabetes. The study will also be looking at the ability of T2-18C3 to improve control of blood sugar levels in diabetics by blocking inflammation in the pancreas.

Description:

This is a phase I, open label study of the safety and pharmacokinetics of T2-18C3 in patients with T2D. Nine patients will receive four biweekly IV infusions of the study drug, T2-18C3, at a dose level of 1.25 mg/kg. These patients will be followed for a total of 90 days to examine safety, pharmacokinetics, and preliminary efficacy.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 7
• Est. primary completion date: October 31, 2012
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• American Diabetes Association (ADA) diagnostic criteria for Type 2 Diabetes (T2D)

• HbA1c >7.0% and = 10%

• Current T2D duration > 3 months at Screening

• T2D and other diseases must be stable. Stable disease is defined as disease which did not require a change in medication or dosing level on 4 or more consecutive days or 7 days in total within 28 days prior to Day 0.

• Age = 18 and = 70 at Screening

• BMI = 23 and = 40 kg/m2

• For female patients of child-bearing age, a negative serum pregnancy test. For patients with reproductive potential, a willingness to utilize adequate contraception (oral contraception plus a mechanical barrier) and not become pregnant (or have their partner[s] become pregnant) during the study

• Agrees not to change diet and exercise regimen during the trial

• Signed and dated Ethics Committee (EC) approved informed consent before any protocol-specific screening procedures are performed

Exclusion Criteria:

• Use of the following medications:

• Daily use of steroids or aspirin = 700 mg per week

• Immunosuppressive treatment

• Thiazolidinediones

• Concomitant treatment with any other therapeutic antibody, or treatment with any biologic agent that blocks the IL-1 or TNFa signaling pathway

• Change in medication for diabetes within 28 days prior to Day 0, defined as a change in dosing level on 4 or more consecutive days or 7 days in total

• Hemoglobin <10.0 g/dL, WBC <3.0 x 103/mm3 , platelet count <125 x 103/mm3, creatinine > 1.5mg/dL, AST/ALT >2 x ULN, alkaline phosphatase >2 x ULN

• Abnormal, untreated T3, T4, thyroglobulin, or TSH levels or history of Grave's disease

• Known HIV antibody, hepatitis B surface antigen and/or hepatitis C antibody

• History of malignancy within 5 years prior to study entry other than carcinoma in situ of the cervix, or adequately treated, nonmetastatic squamous or basal cell carcinoma of the skin

• History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies

• History of tuberculosis, positive PPD test, active atopic disease requiring medication, or asthma

• Infectious disease:

• CRP >30 mg/L, fever, or infection requiring treatment with antibiotics within 3 weeks prior to Screening

• History of recurrent infection or predisposition to infection

• Active leg or foot ulcer

• Immunodeficiency

• Female patients who are pregnant, planning to become pregnant during the course of the study, or breast-feeding

• Receipt of a live (attenuated) vaccine within 3 months prior to Screening

• Major surgery within 28 days prior to Day 0

• Participation in an investigational drug or device trial within 30 days prior to Screening

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 2
• Type 2 Diabetes

Intervention

Drug:
• T2-18C3 therapeutic antibody
1.25 mg/kg Intravenous infusion every 2 weeks for a total of 4 doses.

Locations

Country	Name	City	State
Switzerland	University Hospital of Basel	Basel

Sponsors (1)

Lead Sponsor	Collaborator
Janssen Research & Development, LLC

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety and Tolerability	The safety and tolerability of T2-18C3 will be determined by observing patients for clinical adverse events, changes in vital signs, and changes in laboratory parameters such as hematology and chemistry.	90 days
Secondary	Pharmacokinetics	Serum levels of T2-18C3 will be measured in patients	90 days
Secondary	Preliminary Efficacy	The ability of T2-18C3 to improve glycemic control will be measured by comparing the change in glycosylated hemoglobin levels of patients from baseline to day 90.	90 days